In this study published in Vaccine ... literature, FDA documents, epidemiological databases, and manufacturer data were searched to create a decision-analytical model of RSV over a 2-year timeframe.

Almost all children will get RSV during their first two years, but each year up to 80,000 children are hospitalized due to it. Now, a new FDA approved vaccine can protect your baby — even before ...

2 COVID-19 variant—JN.1 is the parent variant of KP.2. The FDA in June asked vaccine makers to create shots that target the coronavirus’ JN.1 variant, but later changed this recommendation to ...

"Their decision was based on the latest available evidence at that time, including how long protection lasts and how common RSV infection is within different age groups, and they concluded that there ...

Despite 50 years of research, there are currently no RSV ... vaccine. The F protein exists as a trimer in both prefusion and postfusion forms that can elicit neutralizing antibodies. The US FDA ...

The U.S. Food and Drug Administration on Friday authorized the updated version of the protein-based Novavax Covid-19 vaccine for use in people 12 and older. Advertisement One week ago, the FDA ...

After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ... can cause developmental delays, speech problems and motor function ...

A Food and Drug Administration decision is due this week on a proposed ... stomach muscles and prevents proper stomach emptying. The FDA in December 2023 accepted Vanda's application seeking ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

The Biden Administration is pushing back on deciding on the proposed takeover of U.S. Steel by Japanese company Nippon Steel. Many American politicians have opposed this deal over concerns about ...

1 strain of the virus. "Today's authorization provides an additional COVID-19 vaccine option," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. Doses are on ...